ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
← catalyst calendarSponsored by Abivax S.A. (industry) · ABVX — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
636actual
Sites
273
Countries
Argentina, Belgium, Brazil +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-21 | actual | When the study began enrolling |
| Primary completion | 2025-06-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-15 | actual | The whole study's end, after follow-up |
| First posted | 2022-08-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: ABX464 — also filed as Obefazimod
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of subjects who achieve clinical remission per Modified Mayo Score at week 8
measured 8 weeks
Permalink · ABVX's whole pipeline · Catalyst calendar · Every registered study · What changed